Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer
Purpose To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival Methods This study included oncology patients who were hospitalized at two oncology...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2021-02, Vol.53 (2), p.301-307 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 2 |
| container_start_page | 301 |
| container_title | International urology and nephrology |
| container_volume | 53 |
| creator | Bilgetekin, Irem Erturk, Ismail Basal, Fatma Bugdayci Karacin, Cengiz Karadurmus, Nuri Oksuzoglu, Berna Demirci, Umut |
| description | Purpose
To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival
Methods
This study included oncology patients who were hospitalized at two oncology centers between January 1, 2016 and December 31, 2019 for hyponatremia (sodium levels 0.05). In the TpST group, recovery days of the hyponatremia after treatment and the length of hospital stay was shorter and hyponatremia symptoms and hospital complications were less frequent compared to the ST group (
p
|
| doi_str_mv | 10.1007/s11255-020-02623-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2439624175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2439624175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-b41f58ea7b3bab0827fcdfa080a7d31fce470aa5eb8b2aec674b9e4e1fb30d8d3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EotvCC3BAlriUQ2BsJ3GWW1UorVSJA-UcTZwx62pjB9tZtE_Dq-JlC0gcOFiW5v9mfnt-xl4IeCMA9NskhGyaCiSU00pV6UdsJRqtKtl09WO2AgWiEkU5Yacp3QPAugN4yk6U7Nq10GrFftyF7Q7njJ7nSJgn8pk7zzf7OXgspckhHxfiOfC8IZ72foxhIh5swXCeY5ijw1wUMpGyC_4goc9udMuhYPgmxCl44uefby7eX79-x8laMjnxwqYl7twOtwfPGbMr9ol_d3nDDXpD8Rl7YnGb6PnDfca-XH24u7yubj99vLm8uK2M0k2uhlrYpiPUgxpwgE5qa0aL0AHqUQlrqNaA2NDQDRLJtLoe1lSTsIOCsRvVGTs_zi0f-rZQyv3kkqHtFj2FJfWyVutW1kI3BX31D3oflujL6wrVtWXn0LSFkkfKxJBSJNuXPU0Y972A_hBff4yvL_H1v-LrdWl6-TB6GSYa_7T8zqsA6gikIvmvFP96_2fsT8OBqWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486301056</pqid></control><display><type>article</type><title>Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer</title><source>SpringerLink Journals</source><creator>Bilgetekin, Irem ; Erturk, Ismail ; Basal, Fatma Bugdayci ; Karacin, Cengiz ; Karadurmus, Nuri ; Oksuzoglu, Berna ; Demirci, Umut</creator><creatorcontrib>Bilgetekin, Irem ; Erturk, Ismail ; Basal, Fatma Bugdayci ; Karacin, Cengiz ; Karadurmus, Nuri ; Oksuzoglu, Berna ; Demirci, Umut</creatorcontrib><description>Purpose
To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival
Methods
This study included oncology patients who were hospitalized at two oncology centers between January 1, 2016 and December 31, 2019 for hyponatremia (sodium levels < 135 mEq/L) and who received tolvaptan plus supportive treatment (
n
= 22) or supportive treatment only (
n
= 42).
Results
The median age of all the patients was 59 years (range 26–85) and 64.1% of the patients were male. There was no statistically significant difference between patients in the tolvaptan plus supportive treatment (TpST) group and the supportive treatment only (ST) group in terms of gender and age (
p
> 0.05). In the TpST group, recovery days of the hyponatremia after treatment and the length of hospital stay was shorter and hyponatremia symptoms and hospital complications were less frequent compared to the ST group (
p
< 0.05). There was no significant difference between the TpST group and the ST group in terms of overall survival (OS). OS was shorter in men who were non-responders to hyponatremia treatment and had recurrent hyponatremia. Multivariable analysis showed that normal sodium levels after treatment decreased the risk of death.
Conclusion
In the treatment of hyponatremia in cancer patients, TpST was found to have more positive effects on blood sodium levels, length of hospital stay, hospital complications, and hyponatremia symptoms compared to ST. A decreased risk of death was observed in patients with normal sodium levels after treatment.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-020-02623-7</identifier><identifier>PMID: 32869173</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Antidiuretics ; Hyponatremia ; Medicine ; Medicine & Public Health ; Nephrology ; Nephrology - Original Paper ; Oncology ; Patients ; Sodium ; Statistical analysis ; Survival ; Urology</subject><ispartof>International urology and nephrology, 2021-02, Vol.53 (2), p.301-307</ispartof><rights>Springer Nature B.V. 2020</rights><rights>Springer Nature B.V. 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-b41f58ea7b3bab0827fcdfa080a7d31fce470aa5eb8b2aec674b9e4e1fb30d8d3</citedby><cites>FETCH-LOGICAL-c375t-b41f58ea7b3bab0827fcdfa080a7d31fce470aa5eb8b2aec674b9e4e1fb30d8d3</cites><orcidid>0000-0002-7310-9328</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-020-02623-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-020-02623-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32869173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bilgetekin, Irem</creatorcontrib><creatorcontrib>Erturk, Ismail</creatorcontrib><creatorcontrib>Basal, Fatma Bugdayci</creatorcontrib><creatorcontrib>Karacin, Cengiz</creatorcontrib><creatorcontrib>Karadurmus, Nuri</creatorcontrib><creatorcontrib>Oksuzoglu, Berna</creatorcontrib><creatorcontrib>Demirci, Umut</creatorcontrib><title>Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival
Methods
This study included oncology patients who were hospitalized at two oncology centers between January 1, 2016 and December 31, 2019 for hyponatremia (sodium levels < 135 mEq/L) and who received tolvaptan plus supportive treatment (
n
= 22) or supportive treatment only (
n
= 42).
Results
The median age of all the patients was 59 years (range 26–85) and 64.1% of the patients were male. There was no statistically significant difference between patients in the tolvaptan plus supportive treatment (TpST) group and the supportive treatment only (ST) group in terms of gender and age (
p
> 0.05). In the TpST group, recovery days of the hyponatremia after treatment and the length of hospital stay was shorter and hyponatremia symptoms and hospital complications were less frequent compared to the ST group (
p
< 0.05). There was no significant difference between the TpST group and the ST group in terms of overall survival (OS). OS was shorter in men who were non-responders to hyponatremia treatment and had recurrent hyponatremia. Multivariable analysis showed that normal sodium levels after treatment decreased the risk of death.
Conclusion
In the treatment of hyponatremia in cancer patients, TpST was found to have more positive effects on blood sodium levels, length of hospital stay, hospital complications, and hyponatremia symptoms compared to ST. A decreased risk of death was observed in patients with normal sodium levels after treatment.</description><subject>Antidiuretics</subject><subject>Hyponatremia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Nephrology - Original Paper</subject><subject>Oncology</subject><subject>Patients</subject><subject>Sodium</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Urology</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kcFu1DAQhi0EotvCC3BAlriUQ2BsJ3GWW1UorVSJA-UcTZwx62pjB9tZtE_Dq-JlC0gcOFiW5v9mfnt-xl4IeCMA9NskhGyaCiSU00pV6UdsJRqtKtl09WO2AgWiEkU5Yacp3QPAugN4yk6U7Nq10GrFftyF7Q7njJ7nSJgn8pk7zzf7OXgspckhHxfiOfC8IZ72foxhIh5swXCeY5ijw1wUMpGyC_4goc9udMuhYPgmxCl44uefby7eX79-x8laMjnxwqYl7twOtwfPGbMr9ol_d3nDDXpD8Rl7YnGb6PnDfca-XH24u7yubj99vLm8uK2M0k2uhlrYpiPUgxpwgE5qa0aL0AHqUQlrqNaA2NDQDRLJtLoe1lSTsIOCsRvVGTs_zi0f-rZQyv3kkqHtFj2FJfWyVutW1kI3BX31D3oflujL6wrVtWXn0LSFkkfKxJBSJNuXPU0Y972A_hBff4yvL_H1v-LrdWl6-TB6GSYa_7T8zqsA6gikIvmvFP96_2fsT8OBqWQ</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Bilgetekin, Irem</creator><creator>Erturk, Ismail</creator><creator>Basal, Fatma Bugdayci</creator><creator>Karacin, Cengiz</creator><creator>Karadurmus, Nuri</creator><creator>Oksuzoglu, Berna</creator><creator>Demirci, Umut</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7310-9328</orcidid></search><sort><creationdate>20210201</creationdate><title>Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer</title><author>Bilgetekin, Irem ; Erturk, Ismail ; Basal, Fatma Bugdayci ; Karacin, Cengiz ; Karadurmus, Nuri ; Oksuzoglu, Berna ; Demirci, Umut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-b41f58ea7b3bab0827fcdfa080a7d31fce470aa5eb8b2aec674b9e4e1fb30d8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antidiuretics</topic><topic>Hyponatremia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Nephrology - Original Paper</topic><topic>Oncology</topic><topic>Patients</topic><topic>Sodium</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilgetekin, Irem</creatorcontrib><creatorcontrib>Erturk, Ismail</creatorcontrib><creatorcontrib>Basal, Fatma Bugdayci</creatorcontrib><creatorcontrib>Karacin, Cengiz</creatorcontrib><creatorcontrib>Karadurmus, Nuri</creatorcontrib><creatorcontrib>Oksuzoglu, Berna</creatorcontrib><creatorcontrib>Demirci, Umut</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilgetekin, Irem</au><au>Erturk, Ismail</au><au>Basal, Fatma Bugdayci</au><au>Karacin, Cengiz</au><au>Karadurmus, Nuri</au><au>Oksuzoglu, Berna</au><au>Demirci, Umut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>53</volume><issue>2</issue><spage>301</spage><epage>307</epage><pages>301-307</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival
Methods
This study included oncology patients who were hospitalized at two oncology centers between January 1, 2016 and December 31, 2019 for hyponatremia (sodium levels < 135 mEq/L) and who received tolvaptan plus supportive treatment (
n
= 22) or supportive treatment only (
n
= 42).
Results
The median age of all the patients was 59 years (range 26–85) and 64.1% of the patients were male. There was no statistically significant difference between patients in the tolvaptan plus supportive treatment (TpST) group and the supportive treatment only (ST) group in terms of gender and age (
p
> 0.05). In the TpST group, recovery days of the hyponatremia after treatment and the length of hospital stay was shorter and hyponatremia symptoms and hospital complications were less frequent compared to the ST group (
p
< 0.05). There was no significant difference between the TpST group and the ST group in terms of overall survival (OS). OS was shorter in men who were non-responders to hyponatremia treatment and had recurrent hyponatremia. Multivariable analysis showed that normal sodium levels after treatment decreased the risk of death.
Conclusion
In the treatment of hyponatremia in cancer patients, TpST was found to have more positive effects on blood sodium levels, length of hospital stay, hospital complications, and hyponatremia symptoms compared to ST. A decreased risk of death was observed in patients with normal sodium levels after treatment.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>32869173</pmid><doi>10.1007/s11255-020-02623-7</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-7310-9328</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2021-02, Vol.53 (2), p.301-307 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2439624175 |
| source | SpringerLink Journals |
| subjects | Antidiuretics Hyponatremia Medicine Medicine & Public Health Nephrology Nephrology - Original Paper Oncology Patients Sodium Statistical analysis Survival Urology |
| title | Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T05%3A15%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tolvaptan%20treatment%20in%20hyponatremia%20due%20to%20the%20syndrome%20of%20inappropriate%20secretion%20of%20antidiuretic%20hormone%20(SIADH):%20effects%20on%20survival%20in%20patients%20with%20cancer&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Bilgetekin,%20Irem&rft.date=2021-02-01&rft.volume=53&rft.issue=2&rft.spage=301&rft.epage=307&rft.pages=301-307&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-020-02623-7&rft_dat=%3Cproquest_cross%3E2439624175%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2486301056&rft_id=info:pmid/32869173&rfr_iscdi=true |